Understanding Sorafenib-Induced Cardiovascular Toxicity: Mechanisms and Treatment Implications
DOI: https://doi.org/10.2147/dddt.s443107
IF: 4.3188
2024-03-18
Drug Design Development and Therapy
Abstract:Jue Li, 1, &ast Lusha Zhang, 2, &ast Teng Ge, 2 Jiping Liu, 1 Chuan Wang, 1 Qi Yu 1, 2 1 Engineering Research Center of Brain Health Industry of Chinese Medicine, Key Laboratory of Pharmacodynamics and Material Basis of Chinese Medicine of Shaanxi Administration of Traditional Chinese Medicine, Pharmacology of Chinese medicine, Shaanxi University of Chinese Medicine, Xianyang, 712046, People's Republic of China; 2 Shaanxi Key Laboratory of Ischemic Cardiovascular Diseases and Institute of Basic and Translational Medicine, Xi'an Medical University, Xi'an, 710021, People's Republic of China &astThese authors contributed equally to this work Correspondence: Qi Yu; Chuan Wang, Email ; Tyrosine kinase inhibitors (TKIs) have been recognized as crucial agents for treating various tumors, and one of their key targets is the intracellular site of the vascular endothelial growth factor receptor (VEGFR). While TKIs have demonstrated their effectiveness in solid tumor patients and increased life expectancy, they can also lead to adverse cardiovascular effects including hypertension, thromboembolism, cardiac ischemia, and left ventricular dysfunction. Among the TKIs, sorafenib was the first approved agent and it exerts anti-tumor effects on hepatocellular carcinoma (HCC) and renal cell carcinoma (RCC) by inhibiting angiogenesis and tumor cell proliferation through targeting VEGFR and RAF. Unfortunately, the adverse cardiovascular effects caused by sorafenib not only affect solid tumor patients but also limit its application in curing other diseases. This review explores the mechanisms underlying sorafenib-induced cardiovascular adverse effects, including endothelial dysfunction, mitochondrial dysfunction, endoplasmic reticulum stress, dysregulated autophagy, and ferroptosis. It also discusses potential treatment strategies, such as antioxidants and renin-angiotensin system inhibitors, and highlights the association between sorafenib-induced hypertension and treatment efficacy in cancer patients. Furthermore, emerging research suggests a link between sorafenib-induced glycolysis, drug resistance, and cardiovascular toxicity, necessitating further investigation. Overall, understanding these mechanisms is crucial for optimizing sorafenib therapy and minimizing cardiovascular risks in cancer patients. Keywords: sorafenib, vascular endothelial growth factor receptor, hypertension, cardiovascular toxicity, cancer Sorafenib, the first FDA-approved inhibitor of the vascular endothelial growth factor (VEGF) pathway, was initially developed for the treatment of renal cell carcinoma (RCC). Since then, it has been approved for use in hepatocellular carcinoma (HCC), acute myeloid leukemia, sclerofibromatosis, and metastatic melanoma. 1 However, as its clinical applications have expanded, reports of drug resistance and side effects among patients receiving sorafenib treatment have become increasingly common. 2 Notably, when these side effects occur in the cardiovascular system, patients often experience hypertension, thrombosis, and cardiac toxicity. 3 The adverse cardiovascular effects caused by sorafenib may be attributed to the complex interaction between the drug and vasculature. Since sorafenib can block various targets in the VEGF pathway, inhibiting this pathway may disrupt the homeostasis of the vasculature and lead to dysfunction in the cardiovascular system. Therefore, elucidating the underlying mechanism behind sorafenib-induced adverse cardiovascular effects is necessary to prevent these side effects and drug resistance. The VEGF pathway plays a crucial role in promoting angiogenesis during tumor progression, making it an attractive target for therapeutic interventions aimed at suppressing tumor angiogenesis. Consistent with this strategy, numerous inhibitors and neutralizing antibodies have been developed to block VEGFs, VEGF receptors, and their tyrosine kinases. One such inhibitor is sorafenib, also known as Nexavar or sorafenib tosylate, which has been shown to inhibit various targets within the VEGF pathway. 4 Interestingly, sorafenib was originally discovered during a biochemical analysis conducted to evaluate the structure-activity relationship of inhibitor precursors targeting C-RAF kinase, a gene associated with rapid fibrosarcoma growth. It is a diaryl urea compound with a unique dual-action mechanism on both Raf kinase and vascular endothelial growth factor receptors (VEGFRs). 5 Bayer Pharmaceuticals performed high-throughput screening from a pool of 20,000 compounds to identify a potent Raf1 kinase inhibitor. Ultimately, 3-thienyl urea (BAY43-9006), later named sorafenib, was selected for further preclinical development.<su -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal